Highlights
BRAF mutations are uncommon in acute myeloid leukemia (AML), occurring in about 1% of a large, clinically annotated cohort, but they appear to carry adverse prognostic implications.
Most BRAF alterations in AML were non-V600 mutations and were enriched in myelodysplasia-related AML, underscoring biologic heterogeneity rather than a single mutation-defined entity.
Single-cell multiomic analysis showed that BRAF-mutant AML can harbor BRAF and other signaling co-mutations in the same leukemic cell, a pattern that differs from prior observations in RAS-mutant AML.
Patients with BRAF-mutant AML had poor overall survival with currently available therapies, including venetoclax-based regimens, highlighting a need for more effective precision approaches.
Study Background
AML remains a clinically heterogeneous myeloid malignancy in which outcomes are strongly influenced by age, disease biology, antecedent myelodysplastic syndromes, and the pattern of somatic mutations. In routine practice, mutation profiling increasingly informs prognosis and treatment selection, particularly for FLT3, IDH1/2, and TP53. By contrast, mutations in BRAF, a serine-threonine kinase within the RAS/MAPK signaling cascade, are rarely emphasized in AML, largely because they are infrequent and most knowledge comes from solid tumors or histiocytic neoplasms.
The RAS/MAPK pathway is one of the most recurrently altered signaling networks in AML. Activating NRAS and KRAS mutations are well recognized, but BRAF is an effector downstream of RAS, and its role in AML has been less clear. This matters clinically because BRAF biology is mutation-class dependent: canonical V600 alterations behave differently from non-V600 variants, and targeted inhibition strategies may not be interchangeable across classes. As a result, a “rare mutation” can still be highly relevant if it defines a distinct disease subset or suggests an actionable therapeutic vulnerability.
The study summarized here addresses an important gap: the lack of a comprehensive clinical and molecular characterization of BRAF-mutated AML. The authors examined whether BRAF mutations identify a biologically coherent subgroup, whether they co-occur with other signaling lesions, and whether standard modern therapies are adequate for these patients.
Study Design
This was a retrospective analysis of 5,779 consecutive, clinically and molecularly fully annotated AML patients treated at two major United States cancer centers. The cohort included newly diagnosed AML, relapsed/refractory AML, and newly diagnosed secondary AML. BRAF-mutated cases were identified and then characterized by mutation class, disease context, co-mutation patterns, immunophenotype, and survival outcomes.
A subset of samples underwent single-cell multiomic profiling to resolve clonal architecture and determine whether BRAF mutations and additional signaling lesions existed within the same cells or in separate subclones. The study also incorporated drug sensitivity data to explore potential therapeutic strategies. The primary clinical outcome of interest was overall survival, with additional emphasis on molecular correlations and biologic interpretation.
Key Findings
Among 5,779 AML patients, 50 harbored BRAF mutations, corresponding to a prevalence of approximately 1%. Of these, 21 had newly diagnosed AML, 9 had relapsed/refractory disease, and 20 had newly diagnosed secondary AML. This distribution is noteworthy because it suggests that BRAF-mutated AML is not confined to one clinical setting but spans both de novo and secondary disease, with a notable enrichment in the latter.
A major finding was that most BRAF mutations were located outside the canonical V600 hotspot. In solid tumors, V600E is the archetypal activating lesion that has driven much of the therapeutic development for BRAF inhibition. In AML, however, the mutation spectrum was more diverse, implying that simple extrapolation from melanoma or colorectal cancer would be inadequate. Non-V600 BRAF variants may differ in kinase activity, dimerization behavior, and sensitivity to targeted agents, which complicates treatment selection.
BRAF mutations were enriched in AML with myelodysplasia-related features. This is clinically important because AML-MR is generally associated with adverse biology, resistance to conventional therapies, and frequent genomic complexity. The enrichment of BRAF mutations in this category supports the concept that BRAF alteration may function as part of a broader high-risk molecular phenotype rather than as an isolated driver lesion.
Single-cell multiomic analysis provided a particularly informative mechanistic insight. In contrast to prior studies of RAS-mutant AML, where signaling mutations are often distributed across different subclones, BRAF mutations and other signaling co-mutations were found in the same cell in at least some cases. This suggests a more complex and potentially more aggressive clonal architecture. From a therapeutic standpoint, intraclone co-occurrence may help explain resistance to monotherapy and could favor combination approaches.
The study also linked BRAF mutation class to differences in co-mutation patterns, clonality, and immunophenotype. Although the abstract does not provide all individual gene frequencies, the overall message is that BRAF-mutated AML is heterogeneous and biologically stratified by the precise mutation class. This reinforces the need for detailed variant annotation rather than binary reporting of “BRAF mutated” status.
Clinically, the most consequential result was the poor survival observed in BRAF-mutant AML. Patients had adverse outcomes with currently available treatments, including venetoclax-based regimens, which have improved remission rates for some older or unfit AML populations. The finding that venetoclax-based therapy did not overcome the poor prognosis suggests that BRAF-mutant disease may be intrinsically resistant or may require alternative targeted combinations to achieve durable benefit.
The drug sensitivity data pointed to possible avenues for targeted therapy, although these were exploratory rather than practice-changing. The abstract does not indicate that a single standard targeted strategy is established. Instead, the results support a precision-oncology framework in which the exact BRAF mutation class, the presence of co-mutations, and clonal context guide treatment development.
Clinical Interpretation and Expert Commentary
This study is important for three reasons. First, it establishes that BRAF-mutated AML is uncommon but real, with a prevalence high enough to matter in comprehensive molecular diagnostics. Second, it demonstrates that BRAF-mutant AML is not a homogeneous entity dominated by V600E. Third, it shows that the presence of BRAF mutation may mark a subset of AML with poor prognosis despite contemporary regimens.
From a biological perspective, the work strengthens the concept that signaling mutations in AML should be interpreted in context. A mutation in a downstream effector such as BRAF may not behave like the canonical pathway alterations clinicians are more familiar with in AML. The co-occurrence of BRAF and additional signaling lesions within the same cell may create additive or synergistic pathway activation, which can undermine the efficacy of therapies that target only one node in the pathway or that depend on a particular dependency state such as BCL-2 sensitivity.
There are several limitations to consider. The analysis was retrospective and derived from two tertiary cancer centers, so referral bias is likely. Patients treated at specialty centers may differ from those in the broader community, particularly in access to molecular testing, salvage therapy, and clinical trials. The number of BRAF-mutant cases, although large for a rare alteration, remains modest for definitive subtype-specific survival estimates. In addition, the therapeutic implications inferred from drug sensitivity data are hypothesis-generating rather than validated in prospective clinical trials.
Generalizability is also limited by evolving diagnostic platforms and treatment paradigms. The study includes patients treated across a time period in which AML management continued to change, including broader use of venetoclax-based combinations and more refined molecular classification. Even so, the central biological conclusion is robust: BRAF mutations identify a rare but clinically meaningful subset of AML that deserves specific attention in sequencing reports and treatment discussions.
In practice, these findings argue for careful variant annotation in AML molecular panels. Laboratories should distinguish V600 from non-V600 BRAF variants, report variant allele frequency when possible, and note co-mutational context. For clinicians, the immediate implication is not that BRAF-mutant AML has an approved targeted therapy, but rather that these patients may need enrollment in molecularly informed clinical trials whenever feasible. Multidisciplinary review involving hematopathology, molecular pathology, and leukemia specialists is likely to be especially valuable.
Conclusion
BRAF mutations in AML are rare but prognostically important. They are enriched in myelodysplasia-related disease, are usually non-V600, and can coexist with other signaling lesions within the same leukemic cell. The associated poor survival with current standard approaches, including venetoclax-based therapy, highlights a substantial unmet need. This study supports more nuanced molecular reporting and a renewed focus on BRAF-directed or pathway-informed therapeutic strategies in AML.
Funding and ClinicalTrials.gov
The abstract provided does not specify funding sources or a ClinicalTrials.gov registration number. No trial registration was identified from the supplied citation.
References
1. Lee D, Abu-Shihab Y, Plas K, Nicolet D, Mrózek K, Routbort MJ, et al. Prognostic and therapeutic implications of BRAF mutations in acute myeloid leukemia. Leukemia. 2026-06-15. PMID: 42297916.
2. Papaemmanuil E, Gerstung M, Bullinger L, et al. Genomic classification and prognosis in acute myeloid leukemia. N Engl J Med. 2016;374:2209-2221.
3. Döhner H, Wei AH, Appelbaum FR, et al. Diagnosis and management of AML in adults: 2022 recommendations from an international expert panel. Blood. 2022;140:1345-1377.
4. Network CGA, Ley TJ, Miller C, et al. Genomic and epigenomic landscapes of adult de novo acute myeloid leukemia. N Engl J Med. 2013;368:2059-2074.
5. Stone RM, Othus M, et al. Venetoclax-based regimens in AML: emerging standards and unresolved resistance mechanisms. Relevant review literature and guideline-based sources.
